Cinda Biopharmaceutical is an investment holding company mainly engaged in biopharmaceuticals. The company and its subsidiaries are engaged in the research and development of antibody and protein pharmaceutical products, drug sales and distribution, as well as providing consulting and R & D services. The company's main product is Dabeshu (Xindirizumab injection), which is used to treat relapsed or refractory classical Hodgkin's lymphoma. The company's products also include adamumab bioanalogue IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab bioanalogue IBI-305 is used in the treatment of metastatic colorectal cancer and advanced, metastatic or recurrent non-small cell lung cancer (NSCLC). Rituximab bioanalogue IBI-301 is used in the treatment of non-Hodgkin's lymphoma and chronic lymphoblastic leukemia. The company's products are used in the fields of oncology, metabolism, immunology and fundus diseases.
CEO： Dechao Yu
Market： Hong Kong motherboard